Abstract
Hydroxyapatite (HA) has proven in recent years to be one of the most versatile and powerful methods for removing aggregates from antibody preparations. It is effective with IgA, IgG and IgM, and it reduces aggregate levels from above 60% to less than 0.1%. Three basic elution strategies have evolved, one that removes aggregates from a modest proportion of clones, another from the majority, and one that appears to be universally effective. Each has distinct development and process ramifications. This review defines what HA is, how it interacts with various classes of biomolecules, how those interactions are controlled by different elution strategies, and how to determine which approach may be most effective for a particular antibody. Consideration is also given to HAs specific strengths and limitations from an industrial perspective.
Current Pharmaceutical Biotechnology
Title: Antibody Aggregate Removal by Hydroxyapatite Chromatography
Volume: 10 Issue: 4
Author(s): Pete Gagnon and Kevin Beam
Affiliation:
Abstract: Hydroxyapatite (HA) has proven in recent years to be one of the most versatile and powerful methods for removing aggregates from antibody preparations. It is effective with IgA, IgG and IgM, and it reduces aggregate levels from above 60% to less than 0.1%. Three basic elution strategies have evolved, one that removes aggregates from a modest proportion of clones, another from the majority, and one that appears to be universally effective. Each has distinct development and process ramifications. This review defines what HA is, how it interacts with various classes of biomolecules, how those interactions are controlled by different elution strategies, and how to determine which approach may be most effective for a particular antibody. Consideration is also given to HAs specific strengths and limitations from an industrial perspective.
Export Options
About this article
Cite this article as:
Gagnon Pete and Beam Kevin, Antibody Aggregate Removal by Hydroxyapatite Chromatography, Current Pharmaceutical Biotechnology 2009; 10 (4) . https://dx.doi.org/10.2174/138920109788488833
DOI https://dx.doi.org/10.2174/138920109788488833 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Dementia and the Default Mode
Current Alzheimer Research B Cells and Beyond: Therapeutic Opportunities Targeting Inflammation
Inflammation & Allergy - Drug Targets (Discontinued) Endoplasmic Reticulum Dysfunction in Brain Pathology: Critical Role of Protein Synthesis
Current Neurovascular Research An Efficient One-Step Hantzsch Multicomponent Synthesis of 1,4- Dihydropyridines Via a Wells-Dawson Heteropolyacid Catalyst Under Solvent-Free Conditions
Letters in Organic Chemistry Suicidality and Cannabidiol: Opportunities and Challenges
Current Neuropharmacology In Vivo Application of beta Amyloid Oligomers: A Simple Tool to Evaluate Mechanisms of Action and New Therapeutic Approaches
Current Pharmaceutical Design Editorial
Current Pediatric Reviews Kratom and Future Treatment for the Opioid Addiction and Chronic Pain: Periculo Beneficium?
Current Drug Targets Advances in the Immune Pathogenesis and Treatment of Multiple Sclerosis
Central Nervous System Agents in Medicinal Chemistry Current Status and Challenges in Rotigotine Delivery
Current Pharmaceutical Design Hippocampal and Amygdalar Morphological Abnormalities in Alzheimer’s Disease Based on Three Chinese MRI Datasets
Current Alzheimer Research Signaling Pathways Modulating Dependence of Lung Cancer on Mutant Epidermal Growth Factor Receptor and Mechanisms of Intrinsic and Acquired Resistance to Tyrosine Kinase Inhibitors
Current Pharmaceutical Design Identification of Potential MEK1 Inhibitors by Pharmacophore-based Virtual Screening and MD Simulations
Letters in Drug Design & Discovery Clonal Expansion of Mitochondrial DNA Deletions and the Progression of Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets The Role of Intranasal Oxytocin in the Treatment of Patients with Schizophrenia: A Systematic Review
CNS & Neurological Disorders - Drug Targets Increased Serum Total Bile Acids can be Associated with a Small Hematoma Volume and Decreased Clinical Severity During Acute Intracerebral Hemorrhage
Current Neurovascular Research Hydroxypyridinone Derivatives: A Fascinating Class of Chelators with Therapeutic Applications - An Update
Current Medicinal Chemistry Induced Pluripotent Stem Cell-Based Studies of Parkinson's Disease: Challenges and Promises
CNS & Neurological Disorders - Drug Targets The Impact of Malnutrition on the Peripheral Serotoninergic System in Anorexia Nervosa: A Systematic Review
Current Psychiatry Reviews Sudden Death Associated with Complex Treatment of Acute Mania: Case Report and Toxicological Findings
Current Psychopharmacology